

Haematologica
HAEMATOL/2019/240754
Version 3
Potential targeting of FLT3 AML

Alexander J. Ambinder and Mark Levis

Disclosures: Mark Levis: Consulting/honoraria/research funding from Astellas, Fujifilm, Daiichi-Sankyo, Amgen, Agios, Novartis Alexander Ambinder: No disclosures

Contributions: Alexander Ambinder and Mark Levis wrote the manuscript together